Le Lézard
Classified in: Health, Science and technology
Subject: PER

YPrime Announces Executive Appointments


MALVERN, Pa., Aug. 21, 2018 /PRNewswire/ -- YPrime announces two key appointments to its executive management team. These appointments bring industry-leading expertise to help YPrime navigate burgeoning demand for eClinical solutions and a rapidly changing regulatory environment. Mark Maietta will serve as President, in addition to his current role as Chief Commercial Officer. Steve Begley has been promoted to Chief Privacy Officer, in addition to his role as Senior Vice President of Quality and Compliance.

In this role, Mark will provide strategic direction for the company's growth strategy. "I am thrilled to welcome Mark to this new position," said Shawn Blackburn, Chief Executive Officer of YPrime.  "Mark's strong track record in delivering results, and his experience in building high-growth businesses will help YPrime continually evolve as we enter an era where clinical research, powered by digital health, takes the next step forward."

A 25-year veteran of the biopharmaceutical industry, Mark served in several increasingly senior roles for organizations with related service offerings before joining YPrime in 2016.  Most recently, he was Chief Commercial Officer for Clariness, a global provider of digital patient recruitment solutions.

As Chief Privacy Officer, Steve will lead efforts to ensure company-wide privacy, data protection standards, information technology (IT) security and regulatory compliance.

"Data privacy for clinical research participants and sponsors is more critical than ever," explained Blackburn. "Customers rely on YPrime for compliance with global privacy and security regulations and standards, including the Health Insurance Portability and Accountability Act (HIPAA), and the EU's Data security and General Data Protection Regulation (GDPR). 'State of the art' principles and controls for privacy and security are among our top priorities as we expand cloud services to support eCOA, IRT and companion applications. Steve offers a unique combination of talents to help ensure compliance and effective risk management without sacrificing product innovation," he added.

Steve brings more than 15 years providing quality assurance and compliance expertise to organizations within the clinical research industry.

About YPrime

YPrime offers more than a decade of focused work with eClinical systems to expedite and improve the quality of patient management, clinical supplies, drug accountability and clinical data. Cloud-based IRT+ and eCOA platforms enable greater speed, precision and integration in clinical trial management. Data services tools eliminate data silos and help sponsors bring together fragmented clinical research data into contextual information they can act on.

Contact: Katherine Cloninger

Senior Director, Marketing

[email protected]

SOURCE YPrime


These press releases may also interest you

at 02:55
First quarter  Sales of SEK 841 (854) million, a flat growth in local currencies and a decrease of 2% in SEK.Sales per region, in local currencies was +19% in APAC, -2% in EMEA and -14% in Americas.Sales per business area, in local currencies was...

at 02:05
PureTech Health plc ("PureTech" or the "Company") plans to publish its Annual Report and Accounts and financial results for the year ended December 31, 2023, on Thursday, April 25, 2024. A presentation and conference call to discuss the results...

at 02:05
Hansa Biopharma, the pioneer in immunomodulatory enzyme technology for rare IgG mediated diseases, today announced its business update and year-end report for January to March 2024. Highlights for the first quarter of 2024      Strong commercial...

at 01:30
The shares in Aker ASA will be traded ex-dividend NOK 15.50 as from today, 18 April 2024. Investor contact:Fredrik Berge, Head of Investor Relations Aker ASA Tel: +47 450 32 090 E-mail: [email protected] Media contact:Atle Kigen, Head of...

at 00:00
Health Carousel, renowned for its dedication to enhancing the healthcare staffing sector, today unveiled its groundbreaking 'Full Circle of Support' program. This initiative represents a significant investment in the total well-being of its...

17 avr 2024
TaiGen Biotechnology Company, Limited ("TaiGen") announces today that the business partner, Joincare Pharmaceutical, has completed the unblinding of influenza antiviral TG-1000 phase III study. Preliminary data shows that the median time to...



News published on and distributed by: